拉帕蒂尼
癌症研究
肝细胞
衰老
DNA损伤
酪氨酸激酶
免疫系统
细胞生物学
氧化应激
生物
检查点激酶2
巨噬细胞
分泌物
癌细胞
肝损伤
激酶
酪氨酸激酶抑制剂
化学
药理学
信号转导
溶酶体
细胞
毒性
癌症
细胞信号
细胞损伤
肝细胞
免疫学
肝癌
细胞色素P450
细胞凋亡
肝细胞学
作者
Gargi Mukherjee,Abhishek Mitra,Vrinda Joshi,Goutam Chowdhury,Anindita Chakrabarty
摘要
Lapatinib and neratinib are tyrosine kinase inhibitors (TKIs) approved for treating HER2-positive metastatic breast cancer, but their clinical use is limited by hepatotoxicity. Within hepatocytes, cytochrome P450 enzymes produce reactive metabolites of these drugs, causing DNA damage, mitochondrial dysfunction, and oxidative stress, which lead to hepatocyte injury. This cellular stress triggers hepatocyte senescence, a state of growth arrest accompanied by the secretion of pro-inflammatory and tissue-remodeling factors called the senescence-associated secretory phenotype (SASP). SASP significantly modifies the liver microenvironment, influences immune cell behavior, and worsens tissue damage. We show that lapatinib and neratinib induce senescence and SASP in the HepG2 liver cell line. Additionally, SASP from these senescent cells promotes M2-like polarization of RAW264.7 macrophages. Although M2 macrophages are associated with anti-inflammatory responses and tissue repair, their excessive or prolonged activity can lead to tissue damage and fibrosis. Our findings highlight a mechanism by which TKI-induced hepatocyte senescence and SASP modulate the immune response and may contribute to liver toxicity in breast cancer patients. This underscores the importance of targeting senescent cells or SASP factors to reduce liver toxicity and improve treatment outcomes, making the identification of effective senotherapeutics a vital research focus. There hasn't been any literature report demonstrating the effect of TKI-induced liver cell secretome on macrophage polarization.
科研通智能强力驱动
Strongly Powered by AbleSci AI